

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/016,969

Confirmation No.: 7314

Applicant

: Pittner et al.: 14 Dec 2001

TC/A.U.

: 1646

Examiner

: Ruixiang Li

Title

Filed

: Peptide YY and Peptide YY Agonists for Treatment of Metabolic

Disorders

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

## RESPONSE TO OFFICE COMMUNICATION

Sir:

In response to the Office communication concerning the above referenced application, mailed on December 19, 2003, it appears that while the U.S. Patent Office received the Supplemental Amendment dated September 30, 2003, and the Request for Continued Examination filed September 22, 2003 (RCE acknowledged in PAIR), it did not receive the Response that was filed with the RCE. Therefore, Applicants resubmit the following papers:

Copy of Request for Continued Examination (1 page) dated September 22, 2003; Copy of Response to Office Action (10 pages), which accompanied the RCE; Copy of Supplemental IDS (2 pages);

CERTIFICATE OF MAILING (37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing Paper

Signature of Person Mailing Paper

Date of Deposit

USSN: 10/016,969

Reply to Office Communication of December 19, 2003

Page 2 of 2

Copy of Supplemental form PTO-1449 (2 pages);

Copy of the references cited in the PTO-1449;

Copy of Transmittal form (1 page);

Copy of Fee Transmittal form (1 page - in duplicate); and

Copy of return postcard mailed from the U.S. Patent Office acknowledging receipt of the above-referenced materials.

All the above-referenced materials were deposited by first class mail on September 22, 2003.

Applicants respectfully request that the Patent Office consider the Response that accompanied the RCE, filed September 22, 2003, first and then the Supplemental Amendment submitted on September 30, 2003. Applicants submit that upon entry of the amendments, the Supplemental Amendment sets forth the claims as currently pending. The Examiner is encouraged to call the undersigned attorney to discuss any issues related to the prosecution of the instant application.

Applicants believe that no fee is necessitated by the present paper. However, in the event any fees are due or any amount is to be credited, Applicants authorize the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Respectfully submitted,

Mi K. Kim

Reg. No. 44,830

AMYLIN PHARMACEUTICALS, INC. 9360 Towne Centre Drive Suite 110 San Diego, CA 92121

Phone: (858) 552-2200 Facsimile: (858) 552-1936

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: Ú.S. DEPARTMENT OF COMMERCE

,~/	Toddollon Act of 1990, No	——————————————————————————————————————		mation unless it displays a valid OMB control number.	
TRANSMITTAL FORM			Application Number	10/016,969	
			Filing Date	December 14, 2001	
			First Named Inventor	Richard A. Pittner et al.	
(to be used for all co	orrespondence after in	nitial filing)	Art Unit ·	1646	
	· ·		Examiner Name	R. Li	
Total Number of Page	es in This Submission		Attorney Docket Number	0401-UTL-0/18528.010	
		ENCLO	DSURES (check all that apply)		
Fee Transmittal	Form		ment Papers Application)	After Allowance Communication to Group	
Fee Attached	d	☐ Drawin	g(s)	Appeal Communication to Board of Appeals and Interferences	
Amendment / Re	esponse	Licensi	ng-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final		Petition	1	Proprietary Information	
☐ Affidavits/de	claration(s)		n to Convert to a onal Application	Status Letter	
I I Estabaian at Tima Daecas			of Attorney, Revocation e of Correspondence Address	Other Enclosure(s) (please identify below):	
		Termin	al Disclaimer	Postcard	
		st for Refund	Copy of submission dated September 22, 2003. Please see Remarks section for a complete		
	osure Statement	CD, Nu	mber of CD(s)	list of items submitted herewith.	
Certified Copy of Document(s)	Priority	Rema		·	
Response to Mis Incomplete Appli	•	Action (10	pages); Supplemental IDS (2 p	nation (1 page); Response to Office ages); Supplemental form PTO-1449 (2	
Response to Missing pages); Re			ererences cited in the P1O-1449 al form (1 page - in duplicate); a ice acknowledging receipt of the	rransmittal form (1 page); Fee and Return postcard mailed from the U.S. as above-referenced materials.	
	SIGNA	TURE OF A	APPLICANT, ATTORNEY, OI	R AGENT	
Firm <i>or</i> Individual name	Amylin Pharmaceuticals, Inc. Mi K.Kim, Reg. No. 44,830				
Signature	Mishn	•			
Date 1/8/04					
		CEI	RTIFICATE OF MAILING		
Service with sufficie	this correspondence int postage as first c 3-1450 on the date sh	lass mail in	imile transmitted to the USPTO an envelope addressed to: Co	or deposited with the United States Postal ommissioner for Patents, P.O. Box 1450,	
Typed or printed nam		mdai	Halverson		
Signature (	Iman	da	Jahrerson	Date 1804	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

`\	1230
,	1230

Complete if Known					
Application Number	10/016,969	•			
Filing Date	December 14, 2001		· · ·		
First Named Inventor	Richard A. PITTNER et al.				
Examiner Name	R. LI	<del></del>			
Art Unit	1646 <sup>-</sup>	\\			
Attorney Docket No.	0401-UTL-0/18528.010				

METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)				
			3. ADDITIONAL FEES				
☐ Check ☐ Credit card ☐ Money ☐ Other ☐ None ☐ Order			Large Entity Small Entity				
Deposit Accor							
Deposit		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Account	01-0535	1051	130	2051	65	Surcharge - late filing fee or oath	
Number		1052	50	2052.	25	Surcharge - late provisional filing fee or cover sheet.	
Deposit		1053	130 .	1053	130	Non-English specification	
Account Name	Amylin Pharmaceuticals, Inc.	1812	2,520	1812	2,520	For filing a request for reexamination	
The Director is a	uthorized to: (check all that apply)	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
<ul><li>☑ Charge fee(s)</li><li>☑ Charge any ad</li></ul>	indicated below	1805	1,840*	1805	1,8401		
to the above-ident	indicated below, except for the filing fee tified deposit account.	1251	110	2251	55	Extension for reply within first month	·
to the above-lach	FEE CALCULATION	1252	.410	2252	205	Extension for reply within second month	
1. BASIC FIL	ING FEE	1253	930	2253	465	Extension for reply within third month	
	Small Entity Fee Fee <u>Fee Description</u>	1254	1,450	- 2254	725	Extension for reply within fourth month	
	Code (\$) Fee Paid	1255	1,970	2255	985	Extension for reply within fifth month	
1001 750 2	2001 375 Utility filing fee	1401	320	2401	160	Notice of Appeal	
1002 330 2	2002 165 Design filing fee	1402	320	2402·-	160	Filing a brief in support of an appeal	
1003 520 2	2003 260 Plant filing fee	1403	280	2403	140	Request for oral hearing	
	2004 375 Reissue filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1 -		1452	110	2452	<b>55</b>	Petition to revive – unavoidable	
	SUBTOTAL (1) (\$) 0	1453	1,300	2453	650	Petition to revive - unintentional	
2. EXTRA CLAIM	FEEG	1501	1,300	2501	650	Utility issue fee (or reissue)	
		1502	470	2502	235	Design issue fee	
	Claims below Paid	1503	630	2503	315	Plant issue fee	
Total Claims 90	-37 ** = 53 X 9 = 477	1460	130	1460	130	Petitions to the Commissioner	
Independent 14.	-5 ** = 9 X 42 = 378	1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
Multiple		1806	180	1806	180	Submission of Information Disclosure Strnt	
Dependent  Large Entity	X = 0 Small Entity	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
Fee Fee Code (\$)	Fee Fee <u>Fee Description</u> Code (\$)	1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1202 18 1201 84	2202 9 Claims in excess of 20 2201 42 Independent claims in excess of 3	1810	750~	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1203 280	2203 140 Multiple dependent claim, if not paid						<del></del>
1204 84	2204 42 ** Reissue independent claims over original patent	1801 1802	750 900	2801	375 900	Request for Continued Examination (RCE)  Request for expedited examination	375.
1205 18	-		1002	,550	of a design application		
	Other fee (specify)						
SUBTOTAL (2) (\$) 855							
	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 375						
**or number previously paid, if greater; For Reissues, see above			·		•	(\$) 375	,
							•

SUBMITTED BY		T		Co	omplete (if applicable)
Name (Print/Type)	Mi K. Kim	Registration No. Attorney/Agent)	44,830	Telephone	858-458-8494
Signature .	Min.			Date	9/22/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

45.					
TOANORUTTAL		Application Number	10/016,969		
TRANSMITTAL	· ·	Filing Date	December 14, 2001		
FORM		First Named Inventor	Richard A. Pittner et al.		
(to be used for all correspondence after	initial filing)	Art Unit	1646		
		Examiner Name	R. Li		
Total Number of Pages in This Submission	n	Attorney Docket Number	0401-UTL-0/18528.010		
	ENCL	OSURES (check all that apply)			
□ Assemble Transmittal Form		ment Papers Application)	After Allowance Communication to Group		
Fee Attached	☐ Drawin	g(s)	Appeal Communication to Board of Appeals and Interferences		
Amendment / Response	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After Final	Petition	ו	Proprietary Information		
Affidavits/declaration(s)	Affidavits/declaration(s) Petitic Provis		Status Letter		
Extension of Time Request		of Attorney, Revocation e of Correspondence Address	Other Enclosure(s) (please identify below):		
Express Abandonment Request		al Disclaimer st for Refund	RCE FORM PTO-1449 References		
Information Disclosure Statement	CD, NL	imber of CD(s)	Postcard		
Certified Copy of Priority Document(s)	Rema	rks	<u> </u>		
Response to Missing Parts/ Incomplete Application		***************************************			
Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNA	ATURE OF A	APPLICANT, ATTORNEY, O	R AGENT		
Firm or Individual name  Amylin Pharmace Mi K.Kim, Reg. No	uticals, Inc.				
Signature /////	,				

## CERTIFICATE OF MAILING

September 22, 2003

Date

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name Mi K. Kim

Signature Date 9/22/03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



UTILITY PATENT	Date: 9/28/03
Rec'd in the U.S. Patent & T	rademark Office on the date stamped hereon via Certificate of M
Case # 0401-UTZ-0	S/N: 10/014,969 Filed: Dec. 14,2001
Pat #	Issued:
Examiner: R. Li	Art Unit: 1646 Atty: M.K. Kim
Applicant: Pitther ct	<i>al.</i>
Title: Pentide YY a	-d Peptide YY Agonists
I Transmittal (1 ee)	
- Fee transmitted	(10e) in duplicate
- Request for Continu	éd Evanunetrai (1 pg)
- Resonce Affectine	(10 psc)
- Suga 1D5 ( 2 ps	es.)
- Suga PTO (2 mg	e I
a Références	(10 references)
□ Return Postcard	

UTI	LITY PATENT	Date: 9/28/03	
Rec'	d in the U.S. Patent & Trademark Office on the	date stamped nereon via	ertificate of Man.
Case	# 0401-UTZ-0 S/N: 10/014,969	9 Filed: <u>DEC. 14, 2</u>	.001
Pat	u issuea:		
	miner: R. Li Art Unit: /	1646 Atty: M.K.	KIM
App	licant: Pittnee et al.		
	e: Pentide YY and Peptide Y	Y ASOMISTS	
	Transmitted (1 pg)	TPK	
	Fee transmitted (1pe) in duplicate	<del></del>	ष्ट्री
	Roccuest for Continued Examination (1	R)	- <del> </del>
	Response Afterfined (10 psc)	SEP 2 6 20	n2 H
	Supp 105 ( 2 pgs.)		N CI
	Suga PTO (2 page)		
	References & (10 references)	TO DE ADIT	O.F.
	Return Postcard		

ducheted